Arrowhead Pharmaceuticals (ARWR) vs Liquidia (LQDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Liquidia (LQDA) has outperformed Arrowhead Pharmaceuticals (ARWR) over the past year, gaining 87.0% versus a gain of 2.3%. Over five years, LQDA leads with a +1224.3% price change compared with -42.6% for ARWR. Arrowhead Pharmaceuticals is the larger company by market cap ($5.85 billion vs $4.90 billion), about 1.2 times the size, while Liquidia is growing revenue faster (+1031.2% vs -45.6%).
Liquidia converts more of its revenue into profit, with a net margin of -43.5% versus -160.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | LQDA |
|---|---|---|
| Share price | $41.37 | $54.43 |
| Market cap | $5.85B | $4.90B |
| 1-day change | -5.22% | -3.88% |
| YTD return | -37.69% | +57.81% |
| 1-year return | +2.27% | +86.98% |
| 5-year return | -42.56% | +1224.33% |
| Forward P/E | — | 15.12 |
| EPS (TTM) | $-5.11 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $450.82M | $158.32M |
| Revenue growth (YoY) | -45.65% | +1031.18% |
| Net income (latest FY) | $-724.21M | $-68.92M |
| Operating margin | -156.86% | -32.45% |
| Net margin | -160.64% | -43.53% |
| 52-week high | $95.49 | $93.61 |
| 52-week low | $40.43 | $22.31 |
| Distance from 52-week high | -56.68% | -41.85% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +156.39% | +21.50% |
| Average volume | 2.08M | 3.52M |
| Shares outstanding | 141.37M | 90.11M |
| Employees | 1,062 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LQDA has outperformed ARWR by 84.7 percentage points over the past year.
- Liquidia is more profitable, keeping -43.5 cents of every revenue dollar as net income versus -160.6 cents for Arrowhead Pharmaceuticals.
- Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs -45.65%).
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,062 employees
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
ARWR vs LQDA FAQ
Which is bigger, Arrowhead Pharmaceuticals or Liquidia?
Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $5.85B compared with $4.90B for Liquidia (LQDA).
Which stock has performed better over the past year, ARWR or LQDA?
LQDA returned +86.98% over the past 12 months, compared with +2.27% for ARWR (price return, excluding dividends). Past performance does not predict future results.
Are Arrowhead Pharmaceuticals and Liquidia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.